Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (48)	12/2/2001 12:08:48 AM
From: Biomaven	Read Replies (1) \| Respond to of 118

IJ, The cholesterol market is driven by primary care physicians. It's a miracle that KOSP's small sales force has been able to make any impact with them at all. Niaspan scripts have consistently been growing faster than the overall market, and if they can come up with a decent partner for Advicor, I suspect they can do very well. It's good that this thread is active again. For newcomers to the stock there's been some recent KOSP discussion on the Biotech Valuation thread starting at this post: Message 16718552 Peter